TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation

TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation
复制标题

DOI:
10.1196/annals.1358.012
复制
发表时间:
2005-01-01
期刊:
HUMAN IMMUNOLOGY: PATIENT-BASED RESEARCH
影响因子:
--
通讯作者:
Papanicolaou, GA
Papanicolaou, GA
中科院分区:
其他
文献类型:
--
作者:
Kesh, S;Mensah, NY;Papanicolaou, GA

文献摘要

被引文献

相似文献

Toll样受体(TLR)响应烟曲霉分生孢子和菌丝传递信号。在这项初步研究中,我们研究了TLR 1,TLR 4和TLR 6基因的单核苷酸多态性(SNPs)与侵袭性曲霉菌病(IA)的发展之间的关联,在127例异基因造血干细胞移植受者中,包括22例IA患者和105例未受影响的对照组。在模型中考虑了以下SNP及其成对相互作用:TLR 1(239 G> C,743 A> G,914 A> T,1805 G> T),TLR 4(896 A> G,1196 C> T)和TLR 6(359 T> C,745 C> T,764 C> T)。未发现供体SNP与IA风险之间存在关联。受体SNP数据的分析显示,TLR 1 239 G> C(Arg 80> Thr)的存在或TLR 1 743 A> G(Asn 248> Ser)和TLR 6 745 C> T(Ser 249> Pro)两者的存在与IA相关(优势比= 1.30,95%置信区间= 1.13至1.50; P < .001)。使用前瞻性队列的进一步分析可能使我们能够在免疫功能低下患者中确定与1A易感性相关的TLR多态性。
Toll-like receptors (TLRs) transmit signals in response to Aspergillus fumigatus conidia and hyphae. In this preliminary study, we examined the association between single nucleotide polymorphisms (SNPs) in TLR1, TLR4, and TLR6 genes and development of invasive aspergillosis (IA) in 127 allogeneic hematopoietic stem cell transplant recipients consisting of 22 patients with IA and 105 unaffected control subjects. The following SNPs and their pairwise interactions were considered in the model: TLR1 (239G > C, 743A > G, 914A > T, 1805G > T), TLR4 (896A > G, 1196C > T), and TLR6 (359T > C, 745C > T, 764C > T). No association was found between donor SNP and the risk of IA. Analysis of recipient SNP data showed that the presence of TLR1 239G > C (Arg80 > Thr) or the presence of both TLRI 743A > G (Asn248 > Ser) and TLR6 745C > T (Ser249 > Pro) is associated with 1A (odds ratio = 1.30, 95% confidence interval = 1.13 to 1.50; P < .001). Further analyses using a prospective cohort may enable us to identify TLR polymorphisms associated with the susceptibility to 1A within a defined interval among immunocompromised patients.